- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05770492
Deep Learning Assisted Epithelial Basement Membrane Dystrophy Detection
Automated Deep Learning for Detection of Epithelial Basement Membrane Dystrophy Using Optical Coherence Tomography and Longitudinal Reproducibility of Disease Characteristics
Epithelial basement membrane dystrophy, also known as Map-Dot fingerprint dystrophy or Cogan microcystic dystrophy, is a common bilateral dystrophy of the anterior human cornea. According to one study, it affects approximately 2% of the human population. A more recent study even reported basement membrane changes in 25% of the general population. However, due to its clinical and morphological appearance, the disease is probably often overlooked.
Although epithelial basement membrane dystrophy is asymptomatic in many affected patients, there are some important clinical consequences of the disease to consider: Dystrophy is estimated to be the second most common cause of recurrent corneal erosion syndrome and is also an important differential diagnosis of dry eye disease. Therefore, it can cause severe pain in affected patients. In addition, epithelial basement membrane dystrophy plays an important role in the context of cataract surgery, one of the most commonly performed surgeries worldwide: besides the importance of appropriate disease management before surgery to prevent postoperative exacerbation of ocular surface symptoms, epithelial basement membrane dystrophy is also a risk factor for inaccurate preoperative biometry.
In recent years, specific features of epithelial basement membrane dystrophy have been introduced in examination methods other than slit-lamp biomicroscopy, such as epithelial thickness mapping or optical coherence tomography. Due to the recent introduction of a variety of deep learning systems, the application of machine learning could significantly increase the detection rate for epithelial basement membrane dystrophy. Furthermore, to the best of our knowledge, the change in disease characteristics over time is currently unknown.
Therefore, the first part of this study will investigate the ability of an automated deep learning system using optical coherence tomography scans to distinguish between normal human corneas and corneas affected by epithelial basement membrane dystrophy. For this purpose, 100 eyes of 50 patients will be included in both study groups. In an optional 2nd part of the study, a second visit will be planned in patients with epithelial basement membrane dystrophy to investigate the reproducibility of disease characteristics as a secondary outcome.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study aims to investigate the capability of an automated deep learning system using anterior segment optical coherence tomography scans to distinguish between normal human corneas and corneas affected by epithelial basement membrane dystrophy. In an optional substudy, a second visit will be scheduled to investigate the reproducibility of disease characteristics as a secondary outcome.
One-hundred eyes of 50 patients with epithelial basement membrane dystrophy and 100 eyes of 50 healthy subjects will be included in this study. After successful screening, all study participants will undergo one single study visit. During this visit, two questionnaires (Ocular Surface Disease Index, Quality of Vision), two different anterior segment optical coherence tomography devices (MS-39, Anterion), a slit lamp examination including slit lamp photography will be performed.
In an optional substudy, patients with epithelial basement membrane dystrophy will have a second visit, to compare the variability of disease characteristics, including number of maps, dots, fingerprint lines and cysts between the two visits.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Oliver Findl, MD, MBA, FEBO
- Phone Number: +43 1 91021- 57564
- Email: office@viros.at
Study Locations
-
-
-
Vienna, Austria, 1140
- Recruiting
- Vienna Institute for Research in Ocular Surgery (VIROS)
-
Contact:
- Andreas Schlatter, MD
- Phone Number: +43 1 91021- 57564
- Email: a.schlatter@viros.at
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria (Group 1):
- Age 18 or older
- Written informed consent
- Presence of epithelial basement membrane dystrophy
Inclusion Criteria (Group 2):
- Age 18 or older
- Written informed consent
- No corneal pathology in both eyes
Exclusion Criteria:
- Other corneal conditions (such as corneal scarring, fuchs endothelial corneal dystrophy, etc.)
- Pregnancy (pregnancy test will be taken in women of reproductive age), nursing women
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Epithelial Basement Membrane Dystrophy
Patients with epithelial basement membrane dystrophy
|
Two different optical systems (MS-39, Costruzione Strumenti Oftalmici Italy; Anterion optical coherence tomographer, Heidelberg Engineering) will be used for acquisition of cross-sectional scans.
Radial scan patterns will be used for acquisition.
|
|
Healthy
Patients/Subjects without corneal pathologies
|
Two different optical systems (MS-39, Costruzione Strumenti Oftalmici Italy; Anterion optical coherence tomographer, Heidelberg Engineering) will be used for acquisition of cross-sectional scans.
Radial scan patterns will be used for acquisition.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Sensitivity of the deep learning system to detect optical coherence tomography scans with epithelial basement membrane dystrophy on the final test data set
Time Frame: 1 day
|
1 day
|
|
Specificity of the deep learning system to detect optical coherence tomography scans with epithelial basement membrane dystrophy on the final test data set
Time Frame: 1 day
|
1 day
|
|
Area under the curve of the deep learning algorithm on the final test data set
Time Frame: 1 day
|
1 day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Interobserver variability regarding disease diagnosis (normal cornea vs. epithelial basement membrane dystrophy) according to slit lamp photographies
Time Frame: 1 day
|
1 day
|
|
|
Interobserver variability regarding number of maps according to slit lamp photographies
Time Frame: 1 day
|
1 day
|
|
|
Interobserver variability regarding number of dots according to slit lamp photographies
Time Frame: 1 day
|
1 day
|
|
|
Interobserver variability regarding number of fingerprints according to slit lamp photographies
Time Frame: 1 day
|
1 day
|
|
|
Interobserver variability regarding number of cysts according to slit lamp photographies
Time Frame: 1 day
|
1 day
|
|
|
Difference in epithelial thickness mapping between healthy corneas and corneas affected by epithelial basement membrane dystrophy
Time Frame: 1 day
|
1 day
|
|
|
Difference in Ocular Surface Disease Index between healthy subjects and patients affected by epithelial basement membrane dystrophy
Time Frame: 1 day
|
minimum: 0, maximum: 100, higher scores are associated with increased symptoms regarding ocular surface disease
|
1 day
|
|
Difference in Quality of Vision questionnaire score between healthy subjects and patients affected by epithelial basement membrane dystrophy
Time Frame: 1 day
|
0- to 100-unit linear scale, higher scores indicating poorer quality of vision
|
1 day
|
|
Sub-study only: Reproducibility of number of maps between visit 1 and visit 2 according to slit lamp photographies and optical coherence tomography images
Time Frame: 3 months
|
number of corneal maps will be assessed by a clinical investigator at both visits
|
3 months
|
|
Sub-study only: Reproducibility of number of dots between visit 1 and visit 2 according to slit lamp photographies and optical coherence tomography images
Time Frame: 3 months
|
number of corneal dots will be assessed by a clinical investigator at both visits
|
3 months
|
|
Sub-study only: Reproducibility of number of fingerprints between visit 1 and visit 2 according to slit lamp photographies and optical coherence tomography images
Time Frame: 3 months
|
number of corneal fingerprint lines will be assessed by a clinical investigator at both visits
|
3 months
|
|
Sub-study only: Reproducibility of number of cysts between visit 1 and visit 2 according to slit lamp photographies and optical coherence tomography images
Time Frame: 3 months
|
number of corneal cysts will be assessed by a clinical investigator at both visits
|
3 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DL_EBMD
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Map Dot Fingerprint Dystrophy
-
Vienna Institute for Research in Ocular SurgeryNot yet recruitingFuchs Endothelial Dystrophy | Map Dot Fingerprint Dystrophy | Post-penetrating Keratoplasty | Post-Descemet Membrane Endothelial Keratoplasty | Healthy Corneas | Ost-Descemet Stripping Automated Endothelial KeratoplastyAustria
-
Manhattan Eye, Ear & Throat HospitalGenentech, Inc.CompletedPolypoidal Choroidal Vasculopathy | Pseudoxanthoma Elasticum | Pathological Myopia | Retinal Angiomatous Proliferation | Coats' Disease | Idiopathic Retinal Telangiectasia | Multi-focal Choroiditis | Rubeosis Iridis | Von Hippel Lindau Disease | BEST VITELLIFORM MACULAR DYSTROPHY, MULTIFOCAL (Disorder)United States
Clinical Trials on anterior segment optical coherence tomography
-
Minia UniversityCompleted
-
University of LeipzigNot yet recruitingImpact of Iridotomy/Iridectomy Size on Postoperative Pupillary Block and Dysphotopsia Following DMEKDysphotopsia | Descemet Membrane Endothelial Keratoplasty (DMEK) | Pupillary Block After DMEK | Laser Iridotomy / Surgical Iridectomy
-
Assiut UniversityUnknownFemtosecond Laser in Comparison to Moria Microkeratome in Creating Corneal Flaps
-
University of Texas Southwestern Medical CenterCompletedCorneal Edema Secondary to Corneal Endothelial DystrophyUnited States
-
University of California, IrvineBeckman Laser Institute University of California IrvineCompletedCerebral AneurysmUnited States
-
Samsung Medical CenterCompleted
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CompletedTransitional Cell Carcinoma of Urinary TractNetherlands
-
Kasr El Aini HospitalCompletedTractional Retinal Detachment | Diabetic Vitreous HemorrhageEgypt